Decision Resources announced today the availability of a new report on obesity. The report includes information on therapies in development such as Axokine from Regeneron, which may be the first obesity drug to cause weight loss after people stop taking the drug. Decision Resources estimates peak-year sales of Axokine in the range of $150- 300 million. The report also concludes that physicians are expressing interest in the potential use of GlaxoSmithKline's depression and smoking cessation agent, bupropion, for obesity.

(Photo: )

"The market for obesity drugs is significantly underserved," said Christine Farrigan, analyst at Decision Resources. "Based on our findings, there are a limited number of people who are prescribed weight loss medication and those who do receive drugs are disappointed with the lack of results. There is great market potential for pharmaceutical companies developing and marketing drugs for obesity."

Although many people still view obesity as the result of a lack of willpower, a growing body of evidence presents this condition as a complex, chronic disease. Losing weight and maintaining weight loss are exceedingly difficult for many overweight and obese individuals. The report, Obesity, offers invaluable market intelligence to pharmaceutical companies that are developing drugs to treat this disease.

Obesity in the U.S.

The United States will remain the largest and most dynamic market for weight-loss drugs because of the staggering number of obese and overweight individuals and better acceptance of drug treatment for obesity. The majority of weight-loss drug sales will occur in the United States, with the U.S. market representing 74% of sales in 2000, 76% in 2005, and 80% in 2010.


Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Discorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states; Obesity is a Mosaic report.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563 



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources

Contact: Elizabeth Marshall of Decision Resources, +1-781-296-2563,

New Report From Decision Resources Finds Inflammatory Bowel Disease Market To Double By 2011

View Now